Michael R. Jaff, DO - Gilde Healthcare

team
Venture&Growth

All team members
Michael R. Jaff, DO
Operational Partner
United States of America

Michael R. Jaff, DO

Operational Partner

Michael R. Jaff, DO is the Chief Medical Officer and Vice-President of clinical affairs, technology and innovation at Boston Scientific Corporation. A professor of medicine at Harvard Medical School, Dr. Jaff was the President of Newton-Wellesley Hospital from October 2016-December 2019. Prior to that, Dr. Jaff was the inaugural Paul and Phyllis Fireman Endowed Chair of Vascular Medicine and Medical Director of the Fireman Vascular Center at the Massachusetts General Hospital. He is an expert in all aspects of vascular medicine, including peripheral artery disease, venous thromboembolic disease, aneurysmal diseases, and all diagnostic strategies in vascular medicine.

He is the founder of VasCore, the Vascular Ultrasound Core Laboratory, the largest of its’ kind in the United States. VasCore has participated in trial design and independent analysis of vascular laboratory images for over 200 prospective multicenter peripheral vascular device and pharmaceutical trials across 66 countries.

Dr. Jaff has published extensively in the field of Vascular Medicine with over 300 peer-reviewed publications and 10 textbooks, is the Past-President of the Society for Vascular

Medicine and Biology and was the first physician to have received the designation as Master of the Society for Vascular Medicine. He is a Fellow of the American College of Physicians, American College of Cardiology, the American Heart Association, and the Society for Cardiovascular Angiography and Intervention, and is a registered physician in vascular interpretation (RPVI).

In November 2011, Dr. Jaff became an alumnus of Harvard Business School after completing the General Management Program.

Stefan Luzi

Partner Therapeutics
Venture&Growth
Stefan Luzi joined Gilde Healthcare in 2015. He is focusing on venture and growth capital investments in the biopharmaceutical sector. He led several investments and currently represents Gilde on the boards of Lava Therapeutics B.V....

Dr. Paul Parren

Operational Partner
Paul Parren is an internationally recognized antibody drug innovator and developer. Paul was Head of Preclinical Development and Research at Genmab (2002-2017), translating antibody biology successfully into immunotherapies from discovery to the clinic, including approved...

Janke Dittmer

General Partner Healthtech
Venture&Growth
Janke Dittmer joined Gilde in 2011 as a Partner. He led Gilde’s investment in Definiens (acquired by AZ), Sapiens (acquired by Medtronic), Volta Medical, Big Health, FIRE1, Lumeon and Nyxoah (IPO on NASDAQ) and was...